S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
NYSE:BHC

Bausch Health Companies (BHC) Stock Price, News & Analysis

$8.62
+0.02 (+0.23%)
(As of 01:33 PM ET)
Today's Range
$8.56
$8.76
50-Day Range
$8.20
$10.61
52-Week Range
$5.57
$11.46
Volume
1.58 million shs
Average Volume
2.77 million shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Bausch Health Companies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
49.1% Upside
$13.00 Price Target
Short Interest
Healthy
6.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.66mentions of Bausch Health Companies in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
3.04%
From $3.95 to $4.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

179th out of 918 stocks

Pharmaceutical Preparations Industry

68th out of 424 stocks

BHC stock logo

About Bausch Health Companies Stock (NYSE:BHC)

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

BHC Stock Price History

BHC Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
BHC Mar 2024 9.000 call
BHC Mar 2024 9.000 put
BHC Mar 2024 5.500 call
Bausch Health Companies Inc. (BHC)
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/19/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
20,270
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$14.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+51.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-592,000,000.00
Pretax Margin
-4.45%

Debt

Sales & Book Value

Annual Sales
$8.76 billion
Cash Flow
$7.12 per share
Book Value
($0.23) per share

Miscellaneous

Free Float
335,741,000
Market Cap
$3.15 billion
Optionable
Optionable
Beta
0.85
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Thomas J. Appio (Age 62)
    CEO & Director
    Comp: $2.74M
  • Mr. John S. Barresi (Age 51)
    Senior VP, Controller, Chief Accounting Officer & Interim CFO
    Comp: $796.8k
  • Ms. Seana  CarsonMs. Seana Carson (Age 51)
    Executive VP & General Counsel
    Comp: $872.65k
  • Mr. Mirza Dautbegovic
    Senior VP & COO
  • Mr. Josh Coyle
    Senior Vice President of Sales & Salix
  • Ms. Kathleen Fitzpatrick
    Senior VP & Chief HR Officer
  • Dr. Tage Ramakrishna M.D. (Age 50)
    Chief Medical Officer and President of R&D
  • Mr. Jeff Hartness
    Executive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs
  • Dr. Graham Jackson
    Senior VP & Chief Quality Officer
  • Mr. Cees Heiman
    Senior Vice President of Europe & Canada

BHC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings
or view top-rated stocks.

What is Bausch Health Companies' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price objectives for Bausch Health Companies' shares. Their BHC share price targets range from $12.00 to $14.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for BHC
or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2024?

Bausch Health Companies' stock was trading at $8.02 on January 1st, 2024. Since then, BHC stock has increased by 8.7% and is now trading at $8.72.
View the best growth stocks for 2024 here
.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 22,500,000 shares, a decline of 5.4% from the March 15th total of 23,780,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest ratio is currently 8.5 days. Currently, 6.3% of the company's stock are sold short.
View Bausch Health Companies' Short Interest
.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BHC earnings forecast
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) posted its quarterly earnings results on Thursday, February, 22nd. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.14. The company earned $2.41 billion during the quarter, compared to analysts' expectations of $2.29 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 5,147.48% and a negative net margin of 6.76%. Bausch Health Companies's quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.02 earnings per share.

What ETF holds Bausch Health Companies' stock?

LeaderShares Activist Leaders ETF holds 300,679 shares of BHC stock, representing 3.13% of its portfolio.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.3 billion-$9.3 billion, compared to the consensus revenue estimate of $9.0 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Thompson Investment Management Inc. (0.06%), IMC Chicago LLC (0.00%), Range Financial Group LLC (0.02%), Marotta Asset Management (0.00%) and Salem Investment Counselors Inc. (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson and Steven D Miller.
View institutional ownership trends
.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners